Comment on: Concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 2, 2008, Pages 426-428

  Nicholls, John M ^a   Aschenbrenner, Laura M ^b   Paulson, James C ^c   Campbell, Erin R ^b   Malakhov, Michael P ^b   Wurtman, David F ^b   Yu, Mang ^b   Fang, Fang ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b NexBio Inc   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DAS 181; FLUDASE; SIALIDASE FUSION PROTEIN;

ANTIVIRAL ACTIVITY; BACTERIAL COLONIZATION; BACTERIUM ADHERENCE; CELL ADHESION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG SAFETY; ENZYME ACTIVITY; ENZYME BINDING; EPITHELIUM CELL; HUMAN; INFLUENZA; INFLUENZA VIRUS; INFLUENZA VIRUS A H5N1; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; NOTE; PANDEMIC; RESPIRATORY EPITHELIUM; SEASONAL VARIATION; SECONDARY INFECTION; SIALYLATION; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VIRUS ENTRY; VIRUS INFECTIVITY; VIRUS STRAIN;

ANTIVIRAL AGENTS; BACTERIAL ADHESION; DISEASE OUTBREAKS; HUMANS; INFLUENZA, HUMAN; LECTINS; NEURAMINIDASE; PNEUMOCOCCAL INFECTIONS; RECOMBINANT PROTEINS; RESPIRATORY MUCOSA; STREPTOCOCCUS PNEUMONIAE;

EID: 47249119786     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn167     Document Type: Note

References (11)

1. Zhang H. Concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza. J Antimicrob Chemother 2008; 62: 219-23.
2. van der Sluijs KF, van Elden LJ, Nijhuis M et al. Involvement of the platelet-activating factor receptor in host defense against Streptococcus pneumoniae during postinfluenza pneumonia. Am J Physiol Lung Cell Mol Physiol 2006; 290: L194-9.
3. Walsh JJ, Dietlein LF, Low FN et al. Bronchotracheal response in human influenza. Type A, Asian strain, as studied by light and electron microscopic examination of bronchoscopic biopsies. Arch Intern Med 1961; 108: 376-88.
4. Plotkowski MC, Puchelle E, Beck G et al. Adherence of type I Streptococcus pneumoniae to tracheal epithelium of mice infected with influenza A/PR8 virus. Am Rev Respir Dis 1986; 134: 1040-4.
5. Chandrasekaran A, Srinivasan A, Raman R et al. Glycan topology determines human adaptation of avian H5N1 virus hemagglutinin. Nat Biotechnol 2008; 26: 107-13.
6. Paulson JC. In: Conn M, ed. Interactions of Animal Viruses with Cell Surface Receptors. New York, NY: Academic Press, 1985; 131-219.
7. Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: The influenza hemagglutinin. Annu Rev Biochem 2000; 69 531-69.
8. Stray SJ, Cummings RD, Air GM. Influenza virus infection of desialylated cells. Glycobioldgy 2000; 10: 649-58.
9. Chu VC, Whittaker GR. Influenza virus entry and infection require host cell N-linked glycoprotein. Proc Natl Acad Sci USA 2004; 101 18153-8.
10. Malakhov MP, Aschenbrenner LM, Smee DF et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 2006; 50: 1470-9.
11. Belser JA, Lu X, Szretter KJ et al. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis 2007; 196: 1493-9.